Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suzhou Erye pharmaceutical, 51% owned subsidiary of international biopharmaceutical company NeoStem, has passed Chinese State Food and Drug Administration (SFDA) inspection to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility with two cGMP lines.
Subscribe to our email newsletter
Suzhou Erye pharma said that its new facility now has obtained government certification, is now fully operational and is manufacturing products on these two production lines.
The new facility is expected to provide an 50% increase in production capacity over the old facility. Coupled with the approval of the lines earlier in 2010, Erye has relocated over 90% of its 2009 sales to the new facility, placing the process significantly ahead of the original 2011 goal.
Robin Smith, chairman and CEO of NeoStem, said: “Erye’s relocation of these two additional production lines to the new facility will increase capacity in the near term by more than 50%, bringing Erye another step closer to its goal of becoming one of the largest antibiotic producers in Eastern China.”
NeoStem is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the US and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need.